Communications Medicine (Apr 2022)
A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern
- Nina Urke Ertesvåg,
- Julie Xiao,
- Fan Zhou,
- Sonja Ljostveit,
- Helene Sandnes,
- Sarah Lartey,
- Marianne Sævik,
- Lena Hansen,
- Anders Madsen,
- Kristin G. I. Mohn,
- Elisabeth Fjelltveit,
- Jan Stefan Olofsson,
- Tiong Kit Tan,
- Pramila Rijal,
- Lisa Schimanski,
- Siri Øyen,
- Karl Albert Brokstad,
- Susanna Dunachie,
- Anni Jämsén,
- William S. James,
- Adam C. Harding,
- Heli Harvala,
- Dung Nguyen,
- David Roberts,
- PHE Virology group,
- Maria Zambon,
- Oxford collaborative group,
- Alain Townsend,
- Bergen COVID-19 Research Group,
- Nina Langeland,
- Rebecca Jane Cox
Affiliations
- Nina Urke Ertesvåg
- Influenza Centre, University of Bergen
- Julie Xiao
- MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital
- Fan Zhou
- Influenza Centre, University of Bergen
- Sonja Ljostveit
- Influenza Centre, University of Bergen
- Helene Sandnes
- Department of Clinical Science, University of Bergen
- Sarah Lartey
- Influenza Centre, University of Bergen
- Marianne Sævik
- Department of Medicine, Haukeland University Hospital
- Lena Hansen
- Influenza Centre, University of Bergen
- Anders Madsen
- Influenza Centre, University of Bergen
- Kristin G. I. Mohn
- Influenza Centre, University of Bergen
- Elisabeth Fjelltveit
- Influenza Centre, University of Bergen
- Jan Stefan Olofsson
- Influenza Centre, University of Bergen
- Tiong Kit Tan
- MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital
- Pramila Rijal
- MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital
- Lisa Schimanski
- MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital
- Siri Øyen
- Eidsvåg Family Practice
- Karl Albert Brokstad
- Broegelmann Research Laboratory, University of Bergen
- Susanna Dunachie
- Oxford University Hospitals NHS Foundation Trust
- Anni Jämsén
- NIHR Oxford Biomedical Research Centre, University of Oxford
- William S. James
- Sir William Dunn School of Pathology, University of Oxford
- Adam C. Harding
- Sir William Dunn School of Pathology, University of Oxford
- Heli Harvala
- Microbiology Services, NHS Blood and Transplant
- Dung Nguyen
- Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford
- David Roberts
- Clinical, Research and Development, NHS Blood and Transplant
- PHE Virology group
- Maria Zambon
- Virology Reference Department, National Infection Service, Public Health England
- Oxford collaborative group
- Alain Townsend
- MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital
- Bergen COVID-19 Research Group
- Nina Langeland
- Department of Clinical Science, University of Bergen
- Rebecca Jane Cox
- Influenza Centre, University of Bergen
- DOI
- https://doi.org/10.1038/s43856-022-00091-x
- Journal volume & issue
-
Vol. 2,
no. 1
pp. 1 – 11
Abstract
Ertesvåg, Xiao et al. describe a method to evaluate neutralising antibodies to SARS-CoV-2 infection or vaccination, including variants of concern. A second mRNA-vaccine dose results in a broader antibody repertoire in adults, although with reduced cross-reactivity to beta and gamma compared to alpha and delta, particularly in the elderly.
